

ForPatients

by Roche

[Early Breast Cancer](#) [Breast Cancer](#) [Er-Positive Breast Cancer](#) [HER-2 Negative Breast Cancer](#)

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (IidERA Breast Cancer)

Trial Status

Active, not recruiting

Trial Runs In

54 Countries

Trial Identifier

NCT04961996

2021-000129-28,2023-507172-44-00

GO42784

The source of the below information is the publicly available website [ClinicalTrials.gov](#). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT04961996 2021-000129-28,2023-507172-44-00 GO42784

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No